Takeda Pharmaceutical Company Limited

Stephen Mack

William John Farnaby

Richard John Davenport

Susanne Wright

Hannah Canning

William Buffham

Alka Parmar

Martin Teall

Kathryn White

Gemma Liwicki

Anne Stephenson

Louise Dickson

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof wherein Z, R, R, R, R, Rand Rare as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy. The present invention further provides methods of treating at least one disease, disorder, or condition associated with the glutamatergic and GABAergic signalling pathways regulated in full or in part by metabotropic glutamate receptor 7 (mGluR7) by administering a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject. The compound may be a selective agonist of mGluR7, which modulates the release of at least one neurotransmitter in the subject.

MGluR7 agonist compounds for treating mGluR7-regulated diseases, disorders, or conditions

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R, X, m, R, Y, R, Z, n, R, A and B are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

Amide derivatives as lysophosphatidic acid receptor antagonists

Compounds

Growing community of inventors

Cambridge, United Kingdom

Stephen Mack